^
Association details:
| Biomarker: | SORT1 positive |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | sudocetaxel zendusortide (TH 1902) (Tubulin polymerization promoter, Microtubule stabilizer, Sortilin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4493 / 18 - Sudocetaxel Zendusortide (TH1902), a peptide-drug conjugate for the treatment of sortilin-positive (SORT1+) TNBC and Her2-positive breast cancers
Published date:
03/15/2023
Excerpt:
...these preclinical data demonstrate the high anticancer properties of TH1902 against SORT1+ TNBC and Herceptin resistant Her2+ breast cancers.
Source:
Title:
TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer
Published date:
08/12/2021
Excerpt:
By exploiting SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1-positive TNBC-derived cells both in vitro and in two in vivo tumor xenografts models....the docetaxel-TH19P01 conjugate (TH1902) exerted potent antiproliferative and antimigratory activities when tested on TNBC-derived MDA-MB-231 cells....This property allows for selective treatment of SORT1-positive TNBC and makes TH1902 a promising avenue for personalized therapy...
DOI:
10.1111/cas.15086
